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Objectives: Several different methods are currently used to detect antibodies to
Japanese encephalitis virus (JEV) in serum samples or cerebrospinal fluid. These
methods include the plaque reduction neutralization test (PRNT), the hemag-
glutination inhibition (HI) test, indirect immunofluorescence assay (IFA), and
enzyme-linked immunosorbent assay (ELISA). The purpose of this study was to
compare the performance of each method in detecting vaccine-induced anti-
bodies to JEV.
Methods: The study included 29 children who had completed a primary immuni-
zation schedule with an inactivated vaccine against JEV derived frommouse brain
(n Z 15) or a live attenuated SA14-14-2 vaccine (n Z 14). Serum samples were
collected between 3 months and 47 months after the last immunization. The
serum samples were tested by performing the PRNT, HI test, in-house IFA, and
commercial ELISA. The antibody detection rates were compared between tests.
Results: All 29 serum samples were positive with the PRNT, showing antibody
titers from 1:20 to 1:2560. The HI test showed positive rates of 86.7% (13/15) and
71.4% (10/14) in the inactivated and live attenuated vaccine groups, respec-
tively. The results of the IFA for immunoglobulin (Ig)G were positive in 53.3% (8/
15) of children in the inactivated vaccine group and 35.7% (5/14) in the live
attenuated vaccine group. Neither the IFA nor ELISA detected JEV IgM antibodies
in any of the 29 children.ted under the terms of the Creative Commons Attribution Non-Commercial License (http://
) which permits unrestricted non-commercial use, distribution, and reproduction in any
operly cited.
mology, National Institute of Health, Korea Centers for Disease Control and Prevention, Chungbuk,
ase Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
Antibodies for Japanese Encephalitis Virus 287Conclusion: These results show that detection rates of vaccine-induced anti-
bodies to JEV have a wide range (0e100%) depending on the testing method as
well as the time since immunization and individual differences between children.
These findings are helpful in interpreting serological test results for the diagnosis
of Japanese encephalitis in situations where vaccines are widely administered.1. Introduction
Japanese encephalitis (JE), a mosquito-borne disease,
is caused by the JE virus (JEV), which belongs to the
Flavivirus genus within the Flaviviridae family [1]. An
estimated 67,900 cases of JE with 20e30% fatality
occurred throughout the Asian and the Pacific regions in
the early 2010s [2]. Vaccination is the most effective
measure for disease control and extensive immunization
programs have been implemented in Korea, Japan, and
Taiwan [3e5]. Two types of vaccines have been used in
Korea. Inactivated vaccines derived from mouse brain
have been used since the late 1960s. Currently, a three-
dose primary vaccination course at 1e3 years of age (0
day, 7e30 days at 12e23 months of age, and 1 year
after the 2nd dose) and two booster immunizations at the
ages of 6 years and 12 years are recommended by the
National Immunization Program (NIP) [3]. A live
attenuated SA 14-14-2 vaccine has been administered in
the private sector since the late 1990s and was included
in the NIP from 2013. The latest regimen is a one-dose
primary vaccination at 12e23 months of age and one
booster immunization 12 months after the first dose.
There are several methods used to detect the JEV
antibodies induced by vaccination and natural in-
fections; these tools have been used to evaluate the ef-
ficacy of the vaccine and to diagnose patients with the
disease [6e8]. These include the plaque reduction
neutralization test (PRNT), the hemagglutination inhi-
bition (HI) test, an indirect immunofluorescence assay
(IFA), and an enzyme-linked immunosorbent assay
(ELISA). The PRNT has been considered to be the most
reliable method for the evaluation of the efficacy of the
vaccine or patient diagnosis, although its turnaround
time is 5e7 days for most flaviviruses and quality
control remains difficult [7,9]. The PRNT is advanta-
geous in regions where two or more flaviviruses circu-
late together. Because strong cross-reactions occur
between antibodies induced by flavivirus infections, it is
hard to identify the exact pathogens with tools other
than the PRNT [10]. However, more rapid and easier
methods such as ELISA and IFA may be preferable
when only one or two distantly related flavivirus species
are transmitted. Serological tests other than PRNT may
therefore be useful in Korea, where only JE has been
reported, although tick-borne encephalitis virus (TBEV)
has been isolated in ticks and rodents [11,12]. Although
many papers have addressed the detection performance
of each testing method for patient diagnosis[6,7,13e16], no standard or guideline has been estab-
lished for choosing a methodology to detect vaccine-
induced antibodies, although some investigators have
demonstrated a high correlation of HI, ELISA, and IFA
results with that of the PRNT [17,18].
In this study, we compared the performance of each
test in detecting vaccine-induced antibodies to JEV in
vaccinated children.2. Materials and methods
2.1. Serum samples
A total of 29 serum samples was collected from
healthy children who completed the primary JE vaccine
schedule between June 2001 and August 2006. Fifteen
children were vaccinated with an inactivated vaccine
derived from mouse brain (3 doses) and 14 children
were vaccinated with live attenuated SA14-14-2 vaccine
(2 doses). Serum samples were collected from study
participants between 3 months and 47 months after the
last vaccine dose (between May 2006 and March 2007).
The medical history of all participants showed no
apparent history of infection with JEV or other flavivi-
ruses during the study. This study was approved by the
Institutional Review Board and written informed con-
sent was obtained from the parents of the children (IUH
IRB 06-390, Inha University).
2.2. PRNT
BHK-21 cells (ATCC, CCL-10) were initially inoc-
ulated at 4.5  105cells/well in six-well tissue culture
plates and propagated for 48 hours at 37C in a CO2
incubator. Serum samples were inactivated for 30 mi-
nutes in a 56C water-bath and serially diluted two-fold
from 1:5 to 1:1280 in minimum essential medium
(MEM) containing 10% fetal bovine serum (FBS) and
penicillin/streptomycin antibiotics (Gibco, Grand Island,
NY, USA). A 100-mL aliquot of JEV (Nakayama strain)
with 100 plaque-forming units (pfu) was mixed with
equal volumes of diluted serum samples and incubated
for 1 hour at 37C. Each virus/serum mixture (total
volume 200 mL) was inoculated onto the BHK-21 cell
monolayer after draining the culture medium and was
allowed to settle for 1 hour at 37C in a CO2 incubator.
The mixture was removed from the cell monolayer and
each well washed once with phosphate-buffered saline
(PBS). Then 4 mL of pre-warmed overlay medium
consisting of 0.9% Noble agar, penicillin/streptomycin,
288 G.W. Cha, et aland 2% FBS in MEM were poured onto each well. The
plates were placed in a CO2 incubator and the overlay
medium was removed 5 days after inoculation. Each
well was fixed with 10% formalin for 30 minutes and
stained with 1% crystal violet solution (resolved in 70%
methanol). Plate wells were washed with tap water,
dried, and the plaques were counted. The neutralizing
antibody titer (PRNT50) was defined as the reciprocal of
the last serum dilution that showed 50% or more plaque
reduction compared with the plaque counts in the virus-
only control well. PRNT50 titers 1:10 were considered
positive.
2.3. HI test
The HI test was performed using goose erythrocyte
and JEV (Nakayama strain) antigens derived from
mouse brain according to the method described by
Clarke and Casals [19]. Acetone-treated serum samples
were serially diluted two-fold from 1:10 to 1:640. The
HI antibody titer was expressed as the reciprocal of the
highest serum dilution that showed complete inhibition
of hemagglutination (8HA units). HI antibody titers
1:10 were considered positive.
2.4. IFA
Antigen slides were made using BHK-21 cells and
JEV Nakayama strain. Cells were grown in MEM with
10% FBS (MEM-10) in T75 culture flasks until 70e80%
confluence. A 1-mL aliquot of virus stock (2  106 pfu/
mL) was mixed with 2 mL of medium, inoculated on the
cell monolayer, and placed in a CO2 incubator for 1 hour.
The cells were then rinsed once with PBS, detached with
2 mL of trypsin/EDTA and counted with a disposable
hemocytometer. The cell density was adjusted to
1  102 cells/mL in MEM-10 and 30 mL of the diluted
sample were added to wells of Teflon-coated slide glasses
(75  25  1 mm, 12 wells, 5 mm diameter; Tekdon,
Myakka, FL, USA) using an automatic dispenser (Biohit,
Helsinki, Finland). The cells were allowed to attach to the
wells in a CO2 incubator at 37
C for 15e17 hours. The
media were then drained and the cells were fixed with
80% cold acetone for 20 minutes, dried at ambient tem-
perature, and stored at 70C until use.
For immunoglobulin (Ig)G antibody detection, serum
samples were serially diluted two-fold from1:16 to 1:1024
and 25 mL of diluted serum were applied to the antigen
slide wells. After incubation in a moist chamber for 30
minutes at 37C, the serum samples were drained and the
antigen slides were washed in an agitating rack with PBS
for 10 minutes (2  5 minutes). Fluorescein
isothiocyanate-conjugated goat anti-human IgG anti-
bodies (Jackson ImmunoResearch,WestGrove, PA,USA)
were diluted 1:200 in 0.0025% Evans blue solution. Next,
25 mL of the antibodies were added to the wells and the
antigen slides were placed in a moist chamber for 30 mi-
nutes at 37C. The slides were washed again in PBS for 10
minutes and a cover-glasswith a dropofmountingmedium(SigmaeAldrich, St Louis, MO, USA) was applied.
Finally, the slides were examined at 200  magnification
under a fluorescence microscope (Axioskop 2 plus, Carl
Zeiss, Goettingen, Germany) in a dark room.
For IgM antibody detection, serum samples were
treated with rheumatoid factor removal reagent
(Chemicon, CA, USA). The treated sample (1:10 dilu-
tion) was applied to the antigen slides for 1 hour in a
37C incubator. Fluorescein isothiocyanate-conjugated
goat anti-human IgM (Jackson ImmunoResearch) was
used as a secondary antibody under conditions identical
to those used for IgG antibody detection. IFA (West
Grove, PA, USA) antibody titers were expressed as the
reciprocal of the last serum dilution that showed definite
cytoplasmic fluorescence (an apple green color). Anti-
body titers 1:16 and titers 1:10 were considered IgG-
and IgM-positive, respectively.
2.5. IgM capture ELISA
Samples were tested for JEV-specific IgM antibodies
using the commercial JE-Dengue IgM Combo ELISA
test (Panbio, Brisbane, QLD, Australia) according to the
manufacturer’s instructions. The kit was used for the
differential screening of JE and dengue fever. Recom-
binant antigens produced in an insect cell system were
used and 100 mL of serum samples diluted 1:100 were
applied to each reaction well. Panbio units (PU) were
calculated for each sample based on the absorbance at
450 nm. Samples with PU > 11 were considered posi-
tive, PU < 9 negative, and values of PU 9e11 were
equivocal. When PU values for both JE and dengue
fever were >11, a JE to dengue fever ratio was calcu-
lated for differential interpretation. A JE to dengue fever
ratio 1 was considered to be JE and a JE to dengue
fever ratio <1 was to be considered dengue fever.
2.6. IgG ELISA
The presence of JEV-specific IgG antibodies was
tested using the commercial JE Detect IgG ELISA kit
(InBios, Seattle, WA, USA) according to the manufac-
turer’s protocol. Briefly, the micro-titer plate was coated
with recombinant antigens consisting of peptides from
different JEV genes. Fifty microliters of 1:300 diluted
serum samples were applied to the reaction well. The
immune status ratio was calculated for each sample based
on the absorbance at 450 nm. Samples with an immune
status ratio >5 were considered positive, while an im-
mune status ratio <2 were considered to be negative.
Samples with values of 2e5 were considered equivocal.3. Results
The presence of antibodies to JEV after vaccination
was assessed using four serological tests in 29 children
who had completed the primary immunization schedule
with either of two vaccine types (an inactivated vaccine
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Table 1 gives information about the participants and
sampling. The mean  SD time from the last immuni-
zation to serum collection was 27.9  15.6 months and
21.3  15.8 months in the inactivated and live attenu-
ated vaccine groups, respectively. The time difference
between the two groups was not statistically significant
(t Z 1.139, p Z 0.265).
Positivity rates differed according to the testing
method. All 29 (100%) children were positive for
neutralizing antibodies to JEV using the PRNT regard-
less of the vaccine type (Table 2). The HI test was
positive in 13/15 (86.6%) children in the inactivated
vaccine group and in 10/14 (71.4%) children in the live
attenuated vaccine group. The positive rates using the
IgG IFA were 53.3% (8/15) and 35.7% (5/14), respec-
tively. However, none of the 29 children was positive
using the commercial IgG/IgM ELISA or the IgM IFA.
The geometric mean titer (GMT) of neutralizing an-
tibodies in the inactivated vaccine group was higher than
that in the live attenuated vaccine group (292 vs. 195).
However, the difference was not statistically significant
(p > 0.05). Similarly, the differences in the GMT of the
HI test (20 vs. 17) and of the IgG IFA (99 vs. 111)
between the groups were not statistically significant.
The different JEV antibody types observed in each
child were plotted against the time since immunization
(Figure 1). Neutralizing antibodies remained at detect-
able levels until at least 47 months after the last dose of
vaccine. HI and IgG IFA antibodies were also detectable
until 47 months post-immunization, although the
detection rates were relatively low and showed indi-
vidual differences (Table 2, Figure 1). However, the
IgG/IgM ELISA and IgM IFA did not show any positive
results in either vaccine group. There was no correlation
in the antibody titers between the PRNT, HI test, and
IgG IFA (data not shown).4. Discussion
This study measured the duration for which vaccine-
induced antibodies were detectable by currently used
serological tests. This information is valuable forTable 1. Characteristics of the 29 children enrolled in the stud
Characteristics Inactivated
Number of children 15
Number of doses in primary schedule 3
Mean (range) age at time of first dose (mo) 16.4 (10.4
Mean (range) age at time of last dose (mo) 31 (19.6e
Interval between sampling and last dose (mo) 27.9 (3.2e
aRange was relatively wide because one child had a booster shot more
vaccine Z inactivated vaccines derived from mouse brain; live vaccine Z livediagnostic laboratories because vaccine-induced anti-
bodies can interfere with the interpretation of serological
test results for patient diagnosis.
We compared the performance of four serological
tests for detecting vaccine-induced antibodies in chil-
dren who had completed the primary vaccination
schedules recommended by the NIP. The PRNT detec-
ted neutralizing antibodies in all 29 children at least 47
months post-immunization, whereas the commercial
ELISA tests showed no positive reaction. This means
that the PRNT was the most reliable method for inves-
tigating the protective immunity against JEV; the HI test
and IgG IFA showed lower positive rates of
35.7e87.5%. This result disagrees with the findings of
other investigators. Venturi et al [17] examined humoral
immunity and correlation between commercial IgG
ELISA tests, HI, and PRNT in children vaccinated
against TBEV. Serum samples were collected from 36
children 1e4 months (mean 123 days) after they had
received a third immunization dose against TBEV. They
found that all three tests detected antibodies at a
maximum of 4 months after the last vaccine dose and
that there was a good correlation between the antibody
titers. Baldovin et al [20] investigated the persistence of
TBEV antibodies in vaccinated (nZ 126) and naturally
infected (n Z 66) groups. Blood samples from partici-
pants in the vaccinated and natural infection groups
were sampled 3e8 years after the last immunization and
1.4e13.7 years after viral infection, respectively.
Commercial IgG ELISA tests showed 79% and 100%
positive results in the vaccination and natural infection
groups, respectively. Litzba et al [18] evaluated com-
mercial ELISA and IFA in 100 people immunized with
two doses of inactivated Vero cell culture-derived JE
vaccine (IXIARO) on Day 0 and Day 28. Among 78
serum samples collected 7e56 days after the final dose,
50 (64%) and 51 (65%) samples were positive using
IgM ELISA (Panbio) and IgM IFA (Euroimmun,
Lubeck, Germany), respectively. A positive rate 60%
is fairly high compared with only 13% (9/68) of children
being IgM ELISA-positive four weeks after receiving
one dose of live attenuated vaccine, as reported by Park
et al [21]. In the report of Litzba et al [18], serum





e24.2) 14.7 (11.9e24.3) 15.6 (10.4e24.3)
67.7)a 24.9 (18.4e31.6) 28 (18.4e67.7)
47.0) 21.3 (3.0e47.1) 24.7 (3.0e47.1)
than 1 year later than recommended in the schedule. Inactivated
attenuated vaccine.
Table 2. Rates of antibody detection obtained by four serological tests in children vaccinated for Japanese encephalitis.
Test
Inactivated vaccine group (n Z 15) Live attenuated vaccine group (n Z 14)
No. (%) positive GMT No. (%) positive GMT
PRNT 15 (100) 1:292 14 (100) 1:195
HI 13 (86.7) 1:20 10 (71.4) 1:17
IFA (IgG) 8 (53.3) 1:99 5 (35.7) 1:111
IFA (IgM) 0 e 0 e
ELISA (IgG) 0 e 0 e
ELISA (IgM) 0 e 0 e
ELISA Z enzyme-linked immunosorbent assay; GMT Z geometric mean titer; HI Z hemagglutination inhibition test; IFA Z indirect immunofluo-
rescence assay; Ig Z immunoglobulin; PRNT Z plaque reduction neutralization test.
290 G.W. Cha, et altested for IgG antibodies. The IgG ELISA test (InBios)
showed a positive rate of 6.6% (6/91), whereas the IgG
IFA a showed positive rate of 94% (91/97). This result
was in good agreement with our finding that the IgG
ELISA test (InBios) had a lower detection rate than theFigure 1. Comparison of antibody titers obtained using different
schedule with mouse brain inactivated (A; n Z 15) or live attenu
ranged from 1:10 to 1:2560, whereas the IFA antibody titers started
titers (closed boxes), HI titers (closed circles), IFA titers (open circl
are not shown in the plots. 1/x Z serum dilution factor (i.e., 80 or
immunofluorescence assay; PRNT Z plaque reduction neutralizatiother tests. The low detection range observed for the
InBios IgG ELISA test might be due to the antigens used
in the kit, which consisted of a mixture of peptides
produced from different parts of genes. The manufac-
turer states that the kit is not optimized for vaccine-tests in children who had completed a primary immunization
ated vaccines (B; n Z 14). The PRNT and HI antibody titers
from 1:16 in two-fold serial dilutions. Test values: PRNT50%
es). Negative results (i.e., antibody titers less than 1:10 or 1:16)
160). HI Z hemagglutination inhibition test; IFA Z indirect
on test.
Antibodies for Japanese Encephalitis Virus 291induced seroconversion studies. We could not perform
any further evaluation because no other commercial IgG
ELISA kits are available. The use of the kit for diag-
nostic purposes would require an evaluation of patient
samples. Differences in the reported performance of
identical serological tests between studies may be
caused by differences in vaccine type, immunization
schedule, the efficacy of the vaccine itself, or sampling
intervals.
It is well documented that natural flavivirus in-
fections elicit greater immune responses and longer
lasting immunity than vaccine-induced immunity
[13,18,20,22]. Neutralizing antibodies may persist for
years or over a lifetime in natural infections. HI anti-
bodies in patients have been reported to persist at
detectable levels for years or decades. IgG antibodies
may be detectable in patients for years using IFA and
ELISA. Sharma et al [23] reported that IgM ELISA
antibodies were at detectable levels in JE patients for
months and up to a year. Burk et al [14] provided results
with more details and found that an in-house ELISA
could be used to detect JEV IgM and IgG antibodies in
patients at 180 days. Taken together, these studies
confirm that the period of detectable JEV antibodies
induced by vaccination or natural infection depends on
the testing methods and individual differences.
In conclusion, this study shows that the PRNT is the
most reliable method for detecting vaccine-induced JEV
antibodies. We also found that IgM detection using IFA
and ELISA is more suitable for diagnosis because the
chance of confusion with vaccine-induced antibodies
were relatively low in those tests. These findings may
help to improve testing algorithms for JE diagnosis in
situations where vaccines are widely administered.Conflicts of interest
The authors declare no conflicts of interest.
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